Table of Contents

On December 16, 2024, the federal judge overseeing the Valsartan litigation confirmed the selection of five cases for the second set of bellwether trials. These trials are part of the multidistrict litigation (MDL) against the manufacturers of Valsartan, specifically addressing the harmful effects of NDMA contamination in the medication. MDL 2875 includes individuals who were harmed by the contaminated drug, and these bellwether trials will serve as important test cases, offering insights into how other lawsuits in the MDL may be resolved. As such, the outcomes of these trials hold significant implications for all plaintiffs involved in the litigation.

Enter a 10-digit phone number with digits only (e.g., 1234567890)

By clicking the ‘Get a Free Review’ button, I hereby grant consent to be contacted at the phone number above for marketing purposes by Tort Advisor and its partners. I understand this may include an automated calling system, artificial voice, pre-recorded message, or an SMS text message. I consent even if my phone number provided is registered on the Federal or State ‘Do Not Call Registry’. I acknowledge that standard message and data rates may apply. Message frequency varies. Text HELP for help. Text STOP to cancel. Clicking ‘Get a Free Review’ constitutes my electronic signature for authorization to be contacted and my agreement to the Terms and Conditions and [Privacy Policy]. This authorization is not required to qualify for, purchase goods, or receive services.

Partners Off-Canvas (Hidden)